Julie L. Sutcliffe, Ph.D.

 
Department of Internal Medicine, Division of Hematology and Oncology, UC Davis
Department of Biomedical Engineering

Institute for Regenerative Cures (IRC)
Room 1763
2921 Stockton Blvd
Sacramento, CA 95817

Phone: (916) 734-5536
Fax: (916) 734-7572

Email: jlsutcliffe_AT_ucdavis.edu
WWW: https://sutcliffe.bme.ucdavis.edu/

I am committed to excellence in both research and teaching. My research program focusses on the development of molecular imaging agents for clinical applications and my educational program on mentoring scholars in multi-disciplinary research. Like many others I believe that molecular imaging encompasses all aspects of clinical management including early detection, guiding the preclinical development of targeted therapeutics and biomarkers, assisting staging of disease and monitoring response to therapeutics. We truly have a unique opportunity to improve human health care and I am honored and excited to be part of this effort.

The primary emphasis of my research program has focused on the design, synthesis, in vitro evaluation and in vivo screening of targeted molecular imaging agents, with the ultimate goal being the rapid deployment to the clinic. The Sutcliffe lab’s major contribution to the field of molecular imaging has been the development of rapid radiolabeling and screening approaches to expedite the translation of radiolabeled compounds from the bench to the bedside. We embrace technologies and have developed rapid radiolabeling technologies for the incorporation of fluorine-18 into peptides, were the first to publish the application of “click” chemistry in PET and were the first to present a high-throughput approach to the design, synthesis and in vivo evaluation of targeted molecular probes for PET. Our efforts recently culminated in a first-in-human study of a PET imaging probe targeting the cancer-associated integrin α_vβ₆ (NCT03164486).

Selected Publications

Marik J, Sutcliffe JL, Click for PET: Rapid Preparation of [¹⁸F]Fluoropeptides Using Cu(I) Catalyzed 1,3-Dipolar Cycloaddition. Tetrahedron Lett. 2006, 47:6681-84.

Gagnon MK, Hausner SH, Marik J, Abbey CK, Marshall JF, Sutcliffe JL, High-throughput in vivo screening of targeted molecular imaging agents. Proc Natl Acad Sci U S A. 2009, 106:17904-9.

Hausner SH, Bauer N, Hu LY, Knight LM, Sutcliffe JL, The effect of bi-terminal PEGylation of an integrin alpha(v)beta(6)-targeted ¹⁸F-peptide on pharmacokinetics and tumor uptake. J Nucl Med. 2015, 56:784-90.

Hausner SH, Bold RJ, Cheuy LY, Chew HK, Daly ME, Davis RA, Foster CC, Kim EJ, Sutcliffe JL, Preclinical development and first-in-human imaging of the integrin α_vβ₆ with [¹⁸F]α_vβ₆-Binding Peptide in metastatic carcinoma. Clinical Cancer Research, 2019, 25(4):1206-15.